China's Generon breaks new ground with first trial of IL-22
This article was originally published in Scrip
Executive Summary
As one of the few privately owned Chinese biotech companies pursuing clinical trials outside China, Generon earlier this month started a Phase I study of F-652, a recombinant protein containing a human interleukin-22 (IL-22) dimer, in several dozen healthy volunteers in Australia.